Panacea Biotec credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
23.723.722.221.020.2
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−50.7−50.7−87.9−159−219
0.03×0.03×0.03×0.03×0.02×
−0.06×−0.06×−0.11×−0.19×−0.26×
−5.08×−5.08×−0.86×−1.05×−0.21×
−23.17×10.89×3.39×7.92×2.24×
−6.23×−6.23×−15.65×−15.86×−30.87×
2.8%2.8%2.6%2.4%2.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,017 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt20.221.022.223.723.7
Net Debt-219.2-158.9-87.9-50.7-50.7
Total Debt/Equity0.020.030.030.030.03
Net Debt/Equity-0.26-0.19-0.11-0.06-0.06
Total Debt/EBITDA-0.21-1.05-0.86-5.08-5.08
Net Debt/EBITDA2.247.923.3910.89-23.17
Interest Coverage (EBIT/Interest)-30.87-15.86-15.65-6.23-6.23
Total Debt/Total Capital %2.352.442.602.782.78
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.